Published in Mol Cell Proteomics on March 18, 2011
The path from the choroid plexus to the subventricular zone: go with the flow! Front Cell Neurosci (2012) 1.03
Opening Pandora's jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders. Future Neurol (2012) 0.95
Collapsin response mediator protein-2 phosphorylation promotes the reversible retraction of oligodendrocyte processes in response to non-lethal oxidative stress. J Neurochem (2012) 0.81
Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 12.21
Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol (2007) 4.87
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med (2003) 4.86
N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol (2007) 4.63
Axonal damage in acute multiple sclerosis lesions. Brain (1997) 3.88
Mechanisms of axon ensheathment and myelin growth. Nat Rev Neurosci (2005) 3.85
The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science (1989) 3.84
CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat Cell Biol (2002) 3.71
Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med (1999) 3.66
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature (2008) 3.48
Neuronal polarity: from extracellular signals to intracellular mechanisms. Nat Rev Neurosci (2007) 3.31
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
CRMP-2 induces axons in cultured hippocampal neurons. Nat Neurosci (2001) 2.70
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol (2007) 2.30
Relation between physiological function and energy metabolism in the central nervous system. J Neurochem (1977) 2.08
B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol (1999) 2.06
Interplay between components of a novel LIM kinase-slingshot phosphatase complex regulates cofilin. EMBO J (2005) 2.02
Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature (1993) 2.01
Detecting protein-protein interactions by Far western blotting. Nat Protoc (2007) 2.01
Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem (2005) 1.91
The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int (2007) 1.77
Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc Natl Acad Sci U S A (2007) 1.76
Molecular domains of myelinated axons. Curr Opin Neurobiol (2000) 1.72
Alpha-enolase: a target of antibodies in infectious and autoimmune diseases. Autoimmun Rev (2006) 1.66
The voltage-dependent anion channel-1 modulates apoptotic cell death. Cell Death Differ (2005) 1.63
K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat Neurosci (2005) 1.62
Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol (2006) 1.57
Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci (2000) 1.53
Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. Oncogene (2003) 1.52
Cyclophilin A participates in the nuclear translocation of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. J Exp Med (2007) 1.50
Identification of potential CSF biomarkers in ALS. Neurology (2006) 1.50
Identification of cofilin and LIM-domain-containing protein kinase 1 as novel interaction partners of 14-3-3 zeta. Biochem J (2003) 1.39
Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol (2009) 1.36
Molecular mechanisms of node of Ranvier formation. Curr Opin Cell Biol (2008) 1.35
The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci (2004) 1.33
The voltage-dependent anion channel: characterization, modulation, and role in mitochondrial function in cell life and death. Cell Biochem Biophys (2003) 1.33
The glycolytic enzymes, glyceraldehyde-3-phosphate dehydrogenase, triose-phosphate isomerase, and pyruvate kinase are components of the K(ATP) channel macromolecular complex and regulate its function. J Biol Chem (2005) 1.30
Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies. Eur J Immunol (2008) 1.26
The beta-amyloid protein of Alzheimer's disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. Brain (2007) 1.19
Voltage-dependent anion channel 1 is involved in endostatin-induced endothelial cell apoptosis. FASEB J (2008) 1.19
Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol (2005) 1.16
Cofilin-mediated neurodegeneration in Alzheimer's disease and other amyloidopathies. Mol Neurobiol (2007) 1.16
The selective RNA-binding protein quaking I (QKI) is necessary and sufficient for promoting oligodendroglia differentiation. J Biol Chem (2007) 1.15
Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis. Glia (2005) 1.10
Molecular basis of programmed cell death involved in neurodegeneration. Trends Neurosci (2005) 1.09
Analysis of multiple sclerosis cerebrospinal fluid reveals a continuum of clonally related antibody-secreting cells that are predominantly plasma blasts. J Neuroimmunol (2007) 1.08
Antibody cross-linking of myelin oligodendrocyte glycoprotein leads to its rapid repartitioning into detergent-insoluble fractions, and altered protein phosphorylation and cell morphology. J Neurosci (2003) 1.07
Isolation and expression pattern of human Unc-33-like phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): coexistence with Ulip2/CRMP2 in Sema3a- sensitive oligodendrocytes. J Neurosci (2001) 1.07
Glyceraldehyde-3-phosphate dehydrogenase is a GABAA receptor kinase linking glycolysis to neuronal inhibition. J Neurosci (2004) 1.07
Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics (2004) 1.06
Characterization of the N-acetylaspartate biosynthetic enzyme from rat brain. J Neurochem (2003) 1.05
Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol (2006) 1.04
LEBER'S DISEASE WITH SYMPTOMS RESEMBLING DISSEMINATED SCLEROSIS. J Neurol Neurosurg Psychiatry (1964) 1.04
Creatine kinase, an ATP-generating enzyme, is required for thrombin receptor signaling to the cytoskeleton. Proc Natl Acad Sci U S A (2000) 1.02
A Drosophila temperature-sensitive seizure mutant in phosphoglycerate kinase disrupts ATP generation and alters synaptic function. J Neurosci (2004) 1.02
Transketolase and 2',3'-cyclic-nucleotide 3'-phosphodiesterase type I isoforms are specifically recognized by IgG autoantibodies in multiple sclerosis patients. Mol Cell Proteomics (2008) 1.02
The myelin-axolemmal complex: biochemical dissection and the role of galactosphingolipids. J Neurochem (2003) 1.00
Stress proteins in oligodendrocytes: differential effects of heat shock and oxidative stress. J Neurochem (2001) 1.00
Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. J Neurochem (2001) 0.99
Immunoglobulin Fc gamma receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res (2002) 0.97
Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease. Mol Cell Neurosci (2003) 0.97
Focal accumulation of intra-axonal mitochondria in demyelination of the cat optic nerve. Acta Neuropathol (1998) 0.95
Triosephosphate isomerase- and glyceraldehyde-3-phosphate dehydrogenase-reactive autoantibodies in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol (2006) 0.93
Antibodies to myelin/oligodendrocyte-specific protein and myelin/oligodendrocyte glycoprotein signal distinct changes in the organization of cultured oligodendroglial membrane sheets. J Neurochem (1994) 0.93
N-Acetylaspartate synthase is bimodally expressed in microsomes and mitochondria of brain. Brain Res Mol Brain Res (2004) 0.92
Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience (2003) 0.92
A role for voltage-dependent anion channel Vdac1 in polyglutamine-mediated neuronal cell death. PLoS One (2007) 0.91
Antibodies to neuronal structures: innocent bystanders or neurotoxins? Diabetes Care (2005) 0.88
Retrograde transport and differential accumulation of serum proteins in motor neurons: implications for motor neuron diseases. Neurology (1987) 0.85
Novel therapeutic targets for axonal degeneration in multiple sclerosis. J Neuropathol Exp Neurol (2010) 0.85
Triosephosphate isomerase deficiency: consequences of an inherited mutation at mRNA, protein and metabolic levels. Biochem J (2005) 0.85
A heat shock protein gene (Hsp70.1) is critically involved in the generation of the immune response to myelin antigen. Eur J Immunol (2008) 0.84
Association of MBP peptides with Hsp70 in normal appearing human white matter. J Neurol Sci (2006) 0.84
Identification of aldolase as a target antigen in Alzheimer's disease. J Immunol (2005) 0.83
Enolase autoantibodies and retinal function in multiple sclerosis patients. Graefes Arch Clin Exp Ophthalmol (2007) 0.83
Autoantibodies and neurodegeneration in multiple sclerosis. Lab Invest (2008) 0.83
Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol (2004) 0.82
Antibody to myelin basic protein in extracts of multiple sclerosis brain. Immunology (1981) 0.82
Antibodies to human optic nerve in Leber's hereditary optic neuropathy. J Neurol Sci (1995) 0.81
Candidate biomarkers of chronic inflammatory demyelinating polyneuropathy (CIDP): proteome analysis of cerebrospinal fluid. J Neuroimmunol (2009) 0.81
The constitutive heat shock protein-70 is required for optimal expression of myelin basic protein during differentiation of oligodendrocytes. Neurochem Res (1998) 0.81
CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. J Neurol (2004) 0.80
Expression of genes for the myelin-specific proteins in oligodendrocytes in vivo demands the presence of axons. Neurosci Lett (1990) 0.78
Failure of central nervous system myelination in MBP/c-myc transgenic mice: evidence for c-myc cytotoxicity. Oncogene (1998) 0.78
Autoimmunity in diabetic autonomic neuropathy: does the immune system get on your nerves? Diabet Med (1998) 0.78
Thrombin receptor PAR-1 on myelin at the node of Ranvier: a new anatomy and physiology of conduction block. Brain (2008) 0.76
Screening of multiple sclerosis cerebrospinal fluid for autoantibodies. J Neurol Sci (1988) 0.76
Proton magnetic resonance spectroscopy of normal appearing white matter in familial and sporadic multiple sclerosis. J Neurol (2005) 0.75
Cell-mediated immunity to nervous system antigens in diabetic patients with neuropathy. Isr J Med Sci (1983) 0.75
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med (2005) 12.99
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol (2007) 7.45
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67
Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell (2010) 4.62
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med (2009) 4.16
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol (2011) 3.53
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol (2002) 3.01
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast (2003) 2.98
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet (2009) 2.75
MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol (2011) 2.51
Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci (2006) 2.32
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol (2013) 2.26
B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol (2010) 2.17
A review of 5434 percutaneous pediatric central venous catheters inserted by anesthesiologists. Paediatr Anaesth (2013) 2.10
Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis (2004) 2.08
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat (2010) 1.96
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med (2013) 1.88
Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood (2007) 1.81
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res (2006) 1.71
LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med (2002) 1.57
Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ (2002) 1.55
A novel titanium rib bridge system for chest wall reconstruction. Ann Thorac Surg (2009) 1.46
GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc Res (2002) 1.38
Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer (2002) 1.36
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr (2011) 1.34
The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci (2004) 1.33
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience. Oncologist (2013) 1.29
Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons. Dev Biol (2011) 1.26
Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev (2014) 1.24
The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc Natl Acad Sci U S A (2003) 1.24
Radiation protection of medical staff. Eur J Radiol (2010) 1.20
CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis--an intravital microscopy study. J Neuroimmunol (2005) 1.18
Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Ann N Y Acad Sci (2007) 1.13
Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol (2005) 1.11
Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis. Glia (2005) 1.10
Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res (2002) 1.06
Distinct immunomodulatory and migratory mechanisms underpin the therapeutic potential of human mesenchymal stem cells in autoimmune demyelination. Cell Transplant (2012) 1.05
Gender does not influence the susceptibility of C57BL/6 mice to develop chronic experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein. Immunol Lett (2002) 1.05
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol (2007) 1.04
Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG. J Neuroimmune Pharmacol (2009) 1.03
The prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis. Curr Stem Cell Res Ther (2011) 1.02
Leukemia inhibitory factor arrests oligodendrocyte death and demyelination in spinal cord injury. J Neuropathol Exp Neurol (2006) 1.01
Modular transcriptional activity characterizes the initiation and progression of autoimmune encephalomyelitis. J Immunol (2005) 1.01
Regulatory role of p53 in experimental autoimmune encephalomyelitis. J Neuroimmunol (2003) 1.00
Narcolepsy and excessive daytime sleepiness. BMJ (2004) 1.00
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast Cancer Res Treat (2012) 1.00
TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol Cell Biol (2005) 1.00
Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis. Stem Cell Res (2011) 1.00
Multiple sclerosis: a battle between destruction and repair. J Neurochem (2006) 0.99
B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity. Ann Neurol (2015) 0.98
Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain (2012) 0.98
Mesenchymal stem cells for treatment of CNS injury. Curr Neuropharmacol (2010) 0.97
Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol (2007) 0.96
First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology (2012) 0.96
A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol (2006) 0.95
Transplantation of bone marrow transduced to express self-antigen establishes deletional tolerance and permanently remits autoimmune disease. J Immunol (2008) 0.94
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res (2006) 0.94
cDNAs encoding large venom proteins from the parasitoid wasp Pimpla hypochondriaca identified by random sequence analysis. Comp Biochem Physiol C Toxicol Pharmacol (2003) 0.93
Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice. J Neurochem (2003) 0.93
Drug therapy for obstructive sleep apnoea in adults. Cochrane Database Syst Rev (2013) 0.93
Towards a comprehensive view of the primary structure of venom proteins from the parasitoid wasp Pimpla hypochondriaca. Insect Biochem Mol Biol (2004) 0.91
The suppression of T cell apoptosis influences the severity of disease during the chronic phase but not the recovery from the acute phase of experimental autoimmune encephalomyelitis in mice. J Neuroimmunol (2002) 0.91
Increased transcriptional activity of milk-related genes following the active phase of experimental autoimmune encephalomyelitis and multiple sclerosis. J Immunol (2007) 0.91
A consensus statement addressing mesenchymal stem cell transplantation for multiple sclerosis: it's time! Stem Cell Rev (2010) 0.90
Fatal acute varicella-zoster virus hemorrhagic meningomyelitis with necrotizing vasculitis in an HIV-infected patient. Clin Infect Dis (2009) 0.89
Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site identification: determinants and constraints. Biochemistry (2011) 0.89
Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol (2005) 0.89
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast Cancer Res (2014) 0.88
A cis-regulatory sequence driving metabolic insecticide resistance in mosquitoes: functional characterisation and signatures of selection. Insect Biochem Mol Biol (2012) 0.88
The high resolution crystal structure of a native thermostable serpin reveals the complex mechanism underpinning the stressed to relaxed transition. J Biol Chem (2004) 0.88
The application of Fourier transform infrared microspectroscopy for the study of diseased central nervous system tissue. Neuroimage (2011) 0.88
EIF2C is overexpressed and amplified in head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec (2010) 0.87
Bayesian change point detection in monitoring cardiac surgery outcomes. Qual Manag Health Care (2011) 0.87
Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. J Med Chem (2011) 0.87
Early glial responses in murine models of multiple sclerosis. Neurochem Int (2004) 0.87
TNFalpha mediates Schwann cell death by upregulating p75NTR expression without sustained activation of NFkappaB. Neurobiol Dis (2005) 0.87
S1 pocket of a bacterially derived subtilisin-like protease underpins effective tissue destruction. J Biol Chem (2011) 0.87
Maximizing clinical benefit with trastuzumab. Semin Oncol (2004) 0.87
The promise of stem cell and regenerative therapies for multiple sclerosis. J Autoimmun (2008) 0.86
Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol (2003) 0.86
The magnitude and encephalogenic potential of autoimmune response to MOG is enhanced in MOG deficient mice. J Autoimmun (2003) 0.86
Early detection of the chemical changes occurring during the induction and prevention of autoimmune-mediated demyelination detected by FT-IR imaging. Neuroimage (2009) 0.86
Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination. Cell Adh Migr (2012) 0.86
Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev (2015) 0.86
Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast (2002) 0.85
Novel therapeutic targets for axonal degeneration in multiple sclerosis. J Neuropathol Exp Neurol (2010) 0.85
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer (2013) 0.84
IL-5-deficient mice are susceptible to experimental autoimmune encephalomyelitis. Int Immunol (2003) 0.84
Functional properties of myelin oligodendrocyte glycoprotein-reactive T cells in multiple sclerosis patients and controls. J Neuroimmunol (2003) 0.84
A global perspective on avian influenza. Ann Acad Med Singapore (2008) 0.84
Age-dependent changes in the proteome following complete spinal cord transection in a postnatal South American opossum (Monodelphis domestica). PLoS One (2011) 0.84
A molecular survey of a captive wallaby population for periodontopathogens and the co-incidence of Fusobacterium necrophorum subspecies necrophorum with periodontal diseases. Vet Microbiol (2013) 0.84